Immune checkpoint inhibitors (ICIs) immunotherapy facilitates new approaches to achieve precision cancer treatment.
Zhang, D., Wang, M., Liu, G. et al. Novel FABP4+C1q+ macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK/JAK/STAT axis. Cell Death Dis 15, 717 (2024). https://doi.org/10.1038/s41419-024-07074-x.
Leave a reply